Posted by Michael Wonder on 17 Dec 2020
FDA approves GSK’s Benlysta as the first medicine for adult patients with active lupus nephritis in the US
17 December 2020 - Approval builds on nearly 10 years of experience in lupus.
GlaxoSmithKline announced the US FDA has approved Benlysa (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
The approval extends the current indication in the US to include both systemic lupus erythematosus and lupus nephritis for both the intravenous and subcutaneous formulations.
